JY
ALLO icon

Jeff Yass’s Allogene Therapeutics ALLO Stock Holding History

Jeff Yass’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$171K Sell
82,400
-9,700
-11% -$21.3K ﹤0.01% 12090
2026
Q1 		$225K Buy
92,100
+81,200
+745% +$163K ﹤0.01% 11467
2025
Q4 		$14.9K Sell
10,900
-4,700
-30% -$6.2K ﹤0.01% 12008
2025
Q3 		$19.3K Sell
15,600
-60,800
-80% -$72.5K ﹤0.01% 12056
2025
Q2 		$86.3K Buy
76,400
+24,700
+48% +$32.8K ﹤0.01% 11867
2025
Q1 		$75.5K Buy
51,700
+13,800
+36% +$26K ﹤0.01% 11701
2024
Q4 		$80.7K Sell
37,900
-35,600
-48% -$87.8K ﹤0.01% 11464
2024
Q3 		$206K Buy
73,500
+4,300
+6% +$11.5K ﹤0.01% 10419
2024
Q2 		$161K Buy
69,200
+38,500
+125% +$114K ﹤0.01% 10615
2024
Q1 		$137K Buy
30,700
+18,100
+144% +$75.5K ﹤0.01% 10978
2023
Q4 		$40.4K Buy
+12,600
New +$35.7K ﹤0.01% 11794
2023
Q2 		– Sell
-50,900
Closed -$251K – 11977
2023
Q1 		$251K Buy
50,900
+34,800
+216% +$223K ﹤0.01% 10106
2022
Q4 		$101K Buy
16,100
+4,000
+33% +$37K ﹤0.01% 10949
2022
Q3 		$131K Buy
12,100
+1,700
+16% +$23.1K ﹤0.01% 11413
2022
Q2 		$119K Sell
10,400
-28,300
-73% -$251K ﹤0.01% 11286
2022
Q1 		$353K Buy
38,700
+2,400
+7% +$25K ﹤0.01% 9866
2021
Q4 		$542K Sell
36,300
-105,300
-74% -$1.86M ﹤0.01% 8967
2021
Q3 		$3.64M Buy
141,600
+42,700
+43% +$1.01M ﹤0.01% 4559
2021
Q2 		$2.58M Buy
98,900
+41,700
+73% +$1.19M ﹤0.01% 5353
2021
Q1 		$2.02M Sell
57,200
-32,700
-36% -$1.1M ﹤0.01% 5896
2020
Q4 		$2.27M Buy
89,900
+1,000
+1% +$32.6K ﹤0.01% 4827
2020
Q3 		$3.35M Buy
88,900
+20,000
+29% +$754K ﹤0.01% 3678
2020
Q2 		$2.95M Buy
68,900
+23,000
+50% +$832K ﹤0.01% 3835
2020
Q1 		$892K Buy
45,900
+1,800
+4% +$42.9K ﹤0.01% 5662
2019
Q4 		$1.15M Sell
44,100
-22,200
-33% -$611K ﹤0.01% 5270
2019
Q3 		$1.81M Buy
66,300
+11,900
+22% +$339K ﹤0.01% 4415
2019
Q2 		$1.46M Sell
54,400
-21,600
-28% -$602K ﹤0.01% 4836
2019
Q1 		$2.2M Buy
+76,000
New +$2.21M ﹤0.01% 3608

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Jeff Yass's ALLO Position: Q2 2026 in Review

Jeff Yass reduced its Allogene Therapeutics (ALLO) stake by 26% in Q2 2026, selling an estimated $72.7K and leaving 93,641 shares worth $195K. The position accounts for ﹤0.01% of the portfolio, ranked #11981.

Jeff Yass first reported a position in ALLO in Q2 2019 and has held it in 28 quarters since. The position peaked at $5.45M in Q1 2021. 207 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Jeff Yass held 93,641 shares of Allogene Therapeutics worth $195K as of Q2 2026.
  • Jeff Yass sold 33,119 Allogene Therapeutics shares in Q2 2026, an estimated $72.7K.
  • Allogene Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11981 holding.
  • Jeff Yass first reported a position in Allogene Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • Jeff Yass's Allogene Therapeutics position peaked at $5.45M in Q1 2021.
  • 207 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.